The Evolving Role of Imaging in the Management of Renal Cell Carcinoma and Prostate Cancer

The Evolving Role of Imaging in the Management of Renal Cell Carcinoma and Prostate Cancer

Introduction:
In recent years, the field of oncology has witnessed significant advancements in imaging techniques, providing valuable insights into the management of various cancers. This article explores two studies presented at medical conferences that shed light on the challenges and potential solutions in the imaging-based management of renal cell carcinoma (RCC) and prostate cancer.

Imaging Assessment in the Management of Renal Cell Carcinoma:
Renal cell carcinoma is known for its potential delayed response to immunotherapy, making accurate imaging assessment crucial for evaluating treatment outcomes. According to a study presented at ASCO GU 2020, it is recommended to perform two consecutive follow-up imaging studies, at least four weeks apart, to assess response or progression accurately. This approach ensures that any potential delayed response to immunotherapy is accounted for, allowing clinicians to make informed treatment decisions.

Hyperprogression and Pseudoprogression in RCC:
Hyperprogression, a distinct phenomenon observed in RCC and other solid tumors treated with immune checkpoint inhibitors, refers to a rapid increase in tumor growth rate. This can be identified by a minimum twofold increase in tumor size. Additionally, new lesions may appear as a result of an increase in the size of micrometastatic disease, initially too small to be visualized with imaging. These lesions become detectable on post-treatment imaging due to tumor immune cell infiltration. On the other hand, pseudoprogression is caused by immune cell infiltration of the tumor with or without edema. Differentiating between these phenomena is crucial for accurate assessment of disease progression and treatment response. The iRECIST criteria, which consider the immune cell infiltration aspect, differs from the RECIST 1.1 criteria and provides a more comprehensive approach to determining progressive disease.

Pelvic Lymph-Node Staging in Prostate Cancer:
Prostate cancer remains a significant challenge in oncology, and accurate staging is essential for optimal treatment planning. The SALT trial investigated the efficacy of 18F-DCFPyL PET/CT imaging in pelvic lymph-node staging before extended pelvic lymph-node dissection (ePLND) in primary prostate cancer. The findings highlighted that while PSMA PET/CT imaging is a valuable tool for detecting lymph nodes affected by prostate cancer, it cannot replace diagnostic ePLND. Therefore, ePLND remains an important step in accurately assessing the extent of lymph node involvement, despite the advancements in imaging techniques.

Connecting Common Points:
Both studies emphasize the importance of accurate imaging assessment in the management of RCC and prostate cancer. In RCC, the potential delayed response to immunotherapy necessitates careful evaluation with follow-up imaging studies performed several weeks apart. Additionally, distinguishing between hyperprogression, pseudoprogression, and true disease progression is crucial for making informed treatment decisions. Similarly, in prostate cancer, while PSMA PET/CT imaging is valuable for detecting affected lymph nodes, it cannot replace ePLND in pelvic lymph-node staging.

Unique Insights:
These studies shed light on the evolving role of imaging in cancer management. They highlight the need for imaging techniques that capture the dynamic nature of tumor response to treatment. By incorporating criteria that consider immune cell infiltration, such as the iRECIST criteria, a more comprehensive assessment of treatment response can be achieved. Moreover, while imaging techniques continue to advance, there are still certain aspects of cancer staging that require invasive procedures, as seen in the SALT trial.

Actionable Advice:

1. Clinicians should follow the recommended approach of performing two consecutive follow-up imaging studies, at least four weeks apart, to accurately assess treatment response in RCC patients undergoing immunotherapy.
2. Awareness and understanding of the different phenomena, such as hyperprogression and pseudoprogression, are vital for accurate assessment of disease progression. Incorporating criteria like iRECIST can provide a more comprehensive evaluation of treatment response.
3. In prostate cancer, while imaging techniques like PSMA PET/CT are valuable, ePLND remains an essential step in pelvic lymph-node staging. Clinicians should ensure the incorporation of both imaging and surgical procedures for optimal staging accuracy.

Conclusion:
The field of oncology continues to benefit from advancements in imaging techniques, providing valuable insights into the management of renal cell carcinoma and prostate cancer. Accurate assessment of treatment response, understanding phenomena like hyperprogression and pseudoprogression, and incorporating both imaging and surgical techniques are crucial for optimal patient care. As imaging technology continues to evolve, it is important for clinicians to stay updated and utilize these tools effectively in the management of cancer.